Ascendis Pharma A/S

Share Repurchase Program On January 9, 2026, the Company announced that the Board had authorized a $ 120 million share repurchase program (the Share Repurchase Program ).

SEC original ↗Ascendis Pharma A/S — Earnings release (6-K report)6-KMay 7, 2026

Purchases under the Share Repurchase Program may be made from time to time through a variety of methods, which may include open-market purchases, privately negotiated transactions, or other methods permitted under applicable securities laws.

SEC original ↗Ascendis Pharma A/S — Earnings release (6-K report)6-KMay 7, 2026

The Share Repurchase Program does not require the Company to repurchase any specific number of shares, and may be modified, suspended or terminated at any time without notice.

SEC original ↗Ascendis Pharma A/S — Earnings release (6-K report)6-KMay 7, 2026

F- 8 In March 2026, the Company repurchased 254,027 of its ordinary shares for a total consideration of $ 60.0 million with an average price of $ 236.35 under the Share Repurchase Program, with $ 60.0 million remaining for future repurchases as of March 31, 2026.

SEC original ↗Ascendis Pharma A/S — Earnings release (6-K report)6-KMay 7, 2026

The repurchased shares are held by the Company as treasury shares and presented as a deduction within equity.

SEC original ↗Ascendis Pharma A/S — Earnings release (6-K report)6-KMay 7, 2026

As of March 31, 2026, the Board is authorized by the shareholders to repurchase up to 2,471,988 of the Company s ADSs or ordinary shares.

SEC original ↗Ascendis Pharma A/S — Earnings release (6-K report)6-KMay 7, 2026

Priority Review Voucher ( PRV ) With the approval, the FDA issued a Rare Pediatric Disease Priority Review Voucher ( PRV ), which confers priority review to a subsequent drug application that would not otherwise qualify for priority review.

SEC original ↗Ascendis Pharma A/S — Earnings release (6-K report)6-KMay 7, 2026

and Europe Direct, the Company is expanding global reach for our Endocrinology Rare Disease products through exclusive sales and distribution agreements with geographic market leaders ( International Markets ) and under Strategic Collaborations.

SEC original ↗Ascendis Pharma A/S — Earnings release (6-K report)6-KMay 7, 2026

Other Revenue Other revenue is attributable to the Company s Strategic Collaborations, and relates to Novo Nordisk A/S ( Novo Nordisk ), Eyconis, Inc.

SEC original ↗Ascendis Pharma A/S — Earnings release (6-K report)6-KMay 7, 2026

In addition to service conditions, vesting is also contingent upon achievement of long-term strategic goals as evaluated by the Board no later than two weeks prior to each vesting date.

SEC original ↗Ascendis Pharma A/S — Earnings release (6-K report)6-KMay 7, 2026

Sale of Rare Pediatric Disease Priority Review Voucher On May 6, 2026, the Company entered into agreement to sell its Rare Pediatric Disease Priority Review Voucher ( PRV ) to an undisclosed buyer for $ 187.5 million.

SEC original ↗Ascendis Pharma A/S — Earnings release (6-K report)6-KMay 7, 2026

Uncertainty concerning estimates and assumptions could result in outcomes that require a material adjustment to assets and liabilities in future periods.

SEC original ↗Ascendis Pharma A/S — Earnings release (6-K report)6-KMay 7, 2026

While the application of critical accounting estimates is subject to material estimation uncertainties, management s ongoing revisions of critical accounting estimates and underlying assumptions have, except for deferred tax assets, as described below, not revealed any other material impact to any of the periods presented in the unaudited condensed consolidated interim financial statements compared to December 31, 2025.

SEC original ↗Ascendis Pharma A/S — Earnings release (6-K report)6-KMay 7, 2026

Key sources of estimation uncertainty primarily relate to continued global commercial growth, mainly expected revenue growth from YORVIPATH, and development of operating expenses to support growth.

SEC original ↗Ascendis Pharma A/S — Earnings release (6-K report)6-KMay 7, 2026

These forward-looking statements are based on senior management s current expectations, estimates, forecasts and projections about our business and the industry in which we operate and involve known and unknown risks, uncertainties and other factors that are in some cases beyond our control.

SEC original ↗Ascendis Pharma A/S — Earnings release (6-K report)6-KMay 7, 2026

Given these risks and uncertainties, you are cautioned not to rely on such forward-looking statements as predictions of future events.

SEC original ↗Ascendis Pharma A/S — Earnings release (6-K report)6-KMay 7, 2026